期刊文献+

自体造血干细胞混合HLA半相合异基因骨髓移植治疗恶性血液病 被引量:2

Autologous hematopoietic stem cell mixed allogeneic HLA haploidentical bone marrow transplantation in the treatment of hematological malignancies
下载PDF
导出
摘要 目的 :观察自体造血干细胞混合HLA半相合异基因骨髓移植治疗恶性血液病的疗效及移植相关并发症 .方法 :分析 1 995 0 1 / 2 0 0 3 0 1我院 33例自体造血干细胞混合HLA半相合骨髓移植患者的临床资料 .结果 :1 7(5 1 % )例患者发生了轻、中度口腔黏膜炎 ,重症出血性膀胱炎和肝VOD者各 1例 ,白质脑病 1例 ,全身放射治疗后发生脑水肿 1例 ,1例移植期间出现结核性胸膜炎 ,并发间质性肺炎 .对可评估的性别不同的 1 0例供受者性染色体分析发现 3例 (30 % )移植后形成混合嵌合体 ,仅 2例发生皮肤cGVHD .随防 4 2 (6 96 )mo ,1 9例 (5 7.6 % )无病存活 ,4例 (1 2 .1 % )移植相关并发症死亡 ,8例 (2 4 .2 % )术后复发 ,2例 (6 .1 % )发生了移植后MDS .结论 :自体造血干细胞混合HLA半相合异体骨髓移植 ,能够有效诱导GVL效应 ,提高疗效 ,减少复发 ,且并无增加移植相关并发症 . AIM: To investigate clinical outcome and the treatment related complications in patients with hematological malignancies undergoing autologous hematopoietic stem cell mixed allogeneic HLA haploidentical bone marrow transplantation. METHODS: We analyzed retrospectively the clinical data of 33 hematological malignancy patients from January 1995 to January 2003. RESULTS: Seventeen (51%) of all 33 developed mild or moderate oral mucitis,1 severe hemorrhagic cystitis,1 hepatic VOD,1 leukoencephalopathy, 1 cerebral edema after TBI,1 interstitial pneumonia due to tuberculous preurisy during transplantation.10 cases evaluable were analysed: 3 cases developed mixed chimera,and 2 cGVHD. With a median follow up of 42 months (range 6 to 96), 19 patients(57.6%) are still in disease free survival, 4(12.1%) patients died from transplantation related toxicity, 8(24.2%) relapsed post transplantation,2(6.1%) developed MDS post transplantation. CONCLUSION: These results indicate that autologous hematopoietic stem cell mixed allogeneic HLA haploidentical bone marrow transplantation can induce GVL effect and reduce relapse post transplantation,without an increased incidence of transplantation related mortality or toxicity.
出处 《第四军医大学学报》 北大核心 2004年第2期159-162,共4页 Journal of the Fourth Military Medical University
基金 甘肃省自然科学基金资助项目 (ZS0 1 1 A2 5 0 80 Y)
关键词 造血干细胞移植 血液肿瘤 移植物抗宿主病 hematopoietic stem cell transplantation hematologic neoplasms graft vs host disease
  • 相关文献

参考文献11

  • 1[2]Ball ED, Wilson J, Phelps V, et al. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: Results of phase II studies with long-term follow-up [J]. Bone Marrow Transplant, 2000;25(8):823-829.
  • 2[3]Schots R, Van Riet I, Ben Othman T, et al. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia [J]. Bone Marrow Transplant, 2001;28(10):917-922.
  • 3[4]Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose [J]. Blood, 2002;100(2):397-405.
  • 4[5]Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation [J]. Blood, 2002;100(9):3108-3114.
  • 5[7]Sykes M, Sheard M, Sachs DH. Effects of T cell depletion in radiation bone marrow chimeras.I.Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD [J]. J Immunol, 1988;141:2282-2288.
  • 6[10]Sykes M, Harty MW, Szot GL, et al. Interleukin-2 inhibits graft versus host disease promoting activity of CD4+ cells while preserving CD4- and CD8- mediated graft versus leukemia effects [J]. Blood, 1994;83:2560-2569.
  • 7[11]Da WM, Liu Y, Zhong JT et al. Autologous bone marrow transplantation mixed with HLA-haploidentical allogeneic marrow transplantaion for treatment of patients with malignant blood diseases [J]. BMT, 1997;19:107-112.
  • 8[12]Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial [J]. Blood, 2001;97(2):404-409.
  • 9[13]Weisdorf D, Bishop M, Dharan B, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes [J]. Biol Blood Marrow Transplant, 2002;8(4):213-220.
  • 10[14]Yamamoto Y, Wang B, Fukuhara S, et al. Mixed peripheral blood stem cell transplantation for autoimmune disease in BXSB/MpJ mice [J]. Blood, 2002;100(5): 1886-1893.

同被引文献5

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部